100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg) CAH Participants Achieved More Than a 90% Reduction of A4 and 97% Reduction of 17-OHP on Atumelnant (80 mg), Beginning at Two Weeks and Sustained Through 12 Weeks In the ADCS Trial, Atumelnant (80 mg) Normalized 24-hr Urinary Free Cortisol Levels for 100% of Participants (n=5) During Treatment Management to Host Investor Conference Call Today at 4:30 PM ET and Onsite ...

SAN DIEGO, June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at the Endocrine Society Annual Meeting, ENDO 2024, including primary data just published in The New England Journal of Medicine from its CAHtalyst™ Phase 3 registrational studies of crinecerfont in pediatric and adult patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. In addition, ...

-          CAHtalyst™ Pediatric Study Met Primary and Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control     -          30% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose at Week 28 while Maintaining Androgen Control versus 0% of Placebo Participants     -          Favorable Trends in Endpoints Reflecting Supraphysiologic Glucocorticoid Dosing and Androgen Excess  ...

     -          CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While Maintaining Androstenedione Control        -          62.7% of Crinecerfont Participants Achieved a Physiologic Glucocorticoid Dose while Maintaining Androstenedione Control versus 17.5% of Placebo Participants     -          Favorable Trends in Endpoints Reflecting Consequences of Supraphysiologic Glu ...

Cardinal Health, Inc. (NYSE:CAH) Leerink Partners Healthcare Crossroads Conference May 29, 2024 10:00 AM ET Company Participants Matt Sims - Head, IR Aaron Alt - CFO Conference Call Participants Michael Cherny - Leerink Partners Michael Cherny Great. We'll get started now. Good morning, everyone. Welcome to the session of the Leerink Healthcare Crossroads Conference. I'm Mike Cherny, the Healthcare Tech and Distribution Analyst. Much more importantly, we have Cardinal Health CFO, Aaron Alt; and Head of IR, ...

Cardinal Health, Inc. (NYSE:CAH) Leerink Partners Healthcare Crossroads Conference May 29, 2024 10:00 AM ET Company Participants Matt Sims - Head, IR Aaron Alt - CFO Conference Call Participants Michael Cherny - Leerink Partners Michael Cherny Great. We'll get started now. Good morning, everyone. Welcome to the session of the Leerink Healthcare Crossroads Conference. I'm Mike Cherny, the Healthcare Tech and Distribution Analyst. Much more importantly, we have Cardinal Health CFO, Aaron Alt; and Head of IR, ...

Cardinal Health (CAH) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this prescription drug distributor have returned -6.9% over the past month versus the Zacks S&P 500 composite's +5% change. The Zacks Medical - Dental Supplies industry, to which Cardinal belongs, has gained 0.6% over this period. Now the key question is: Where could the stock be headed ...

Cardinal Health, Inc. (NYSE:CAH) BofA Securities 2024 Health Care Conference May 14, 2024 11:00 AM ET Company Participants Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Unidentified Analyst CEO, Jason Hollar and CFO, Aaron Alt. First off, thank you both for joining us today. Now, Jason, you've been with the company since COVID began and we're finally entering a more normalized operating environment. And I guess as we sit here today, what are you most ...

Cardinal Health (CAH) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this prescription drug distributor have returned -10% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Medical - Dental Supplies industry, to which Cardinal belongs, has lost 4.9% over this period. Now the key question is: Where could the stock be headed in the near te ...

For the quarter ended March 2024, Cardinal Health (CAH) reported revenue of $54.91 billion, up 8.8% over the same period last year. EPS came in at $2.08, compared to $1.74 in the year-ago quarter.The reported revenue represents a surprise of -1.63% over the Zacks Consensus Estimate of $55.82 billion. With the consensus EPS estimate being $1.95, the EPS surprise was +6.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...